Alleviation of hypopigmentary problems (leukoderma) in humans remains, unfortunately, an unresolved problem. Our laboratories have designed superpotent melanotropins that exhibit ultraprolonged biological activity and that are resistant to inactivation by serum enzymes. These melanotropins are 10,000 times more active than Alpha-melanotropin (Alpha-melanocyte stimulating hormone, Alpha-MSH) in stimulating melanin synthesis within follicular melanocytes of mice. Most importantly, we have demonstrated that these melanotropins, when applied topically to skin of the mouse, are transported trandermally and subsequently activate melanogenesis within hair follicles. These results have important implications for the use of melanotropins in the successful treatment of hypopigmentary problems in humans. We plan to do the following: 1) Develop strategies for the synthesis of melanotropic peptides that posses structural characteristics that will allow them to more readily pass through the stratum corneum to the underlying epidermal melanocytes; 2) Develop strategies for the formulation of these melanotropins at different concentrations into vehicles for topical application (transdermal delivery) to the skin or mice; 3) Determine the melanogenic potential of the melanotropin analogs by monitoring follicular melanogenesis in response to subcutaneously injected and topically applied melanotropin analogs; 4) Develop a human (cadaver) skin model for the study of the transdermal delivery of topically applied melanotropic peptides; 5) Determine whether those melanotropins that are successfully delivered transdermally in the mouse are similarly effective in enhancing melanogenesis in both normal and hypopigemented areas of human skin; 6) Determine the possible systemic side effects of melanotropins to ensure the safe use of topically applied melanotropins in humans. The proposed studies may produce valuable clinical approaches for the treatment of the hypomelanoses. An ultimate outcome of these studies may be to provide a rational method for the hormonal stimulation of """"""""suntanning"""""""" in humans.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR036021-03
Application #
3157445
Study Section
General Medicine A Subcommittee 2 (GMA)
Project Start
1985-09-01
Project End
1988-08-31
Budget Start
1987-09-01
Budget End
1988-08-31
Support Year
3
Fiscal Year
1987
Total Cost
Indirect Cost
Name
University of Arizona
Department
Type
Schools of Medicine
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85722
Dawson, B V; Hadley, M E; Levine, N et al. (1990) In vitro transdermal delivery of a melanotropic peptide through human skin. J Invest Dermatol 94:432-5
al-Obeidi, F; Hruby, V J; Hadley, M E et al. (1990) Design, synthesis, and biological activities of a potent and selective alpha-melanotropin antagonist. Int J Pept Protein Res 35:228-34
Marwan, M M; Jiang, J W; Castrucci, A M et al. (1990) Psoralens stimulate mouse melanocyte and melanoma tyrosinase activity in the absence of ultraviolet light. Pigment Cell Res 3:214-21
Castrucci, A M; Hadley, M E; Sawyer, T K et al. (1989) Alpha-melanotropin: the minimal active sequence in the lizard skin bioassay. Gen Comp Endocrinol 73:157-63
Hadley, M E; Marwan, M M; al-Obeidi, F et al. (1989) Linear and cyclic alpha-melanotropin [4-10]-fragment analogues that exhibit superpotency and residual activity. Pigment Cell Res 2:478-84
Al-Obeidi, F; Castrucci, A M; Hadley, M E et al. (1989) Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. J Med Chem 32:2555-61
Al-Obeidi, F; Hruby, V J; Castrucci, A M et al. (1989) Design of potent linear alpha-melanotropin 4-10 analogues modified in positions 5 and 10. J Med Chem 32:174-9